Search results for "Bioavailability"

showing 10 items of 301 documents

Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors

2017

Abstract Introduction Radiolabeled bombesin (BBN)-analogs have been proposed for diagnosis and therapy of gastrin-releasing peptide receptor (GRPR)-expressing tumors, such as prostate, breast and lung cancer. Metabolic stability represents a crucial factor for the success of this approach by ensuring sufficient delivery of circulating radioligand to tumor sites. The amide-to-triazole switch on the backbone of DOTA-PEG 4 -[Nle 14 ]BBN(7–14) ( 1 ) was reported to improve the in vitro stability of resulting 177 Lu-radioligands. On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and …

MaleCancer ResearchBiodistributionStereochemistryPharmacology[ CHIM ] Chemical Sciences030218 nuclear medicine & medical imagingPolyethylene Glycols03 medical and health scienceschemistry.chemical_compoundHeterocyclic Compounds 1-RingMice0302 clinical medicineIn vivoCell Line TumorRadioligandAnimalsHumans[CHIM]Chemical SciencesRadiology Nuclear Medicine and imagingTissue DistributionNeprilysinTumor targeting GRPR-radioligand 177Lu-bombesin Triazolyl-bombesin NEP-inhibitionPhosphoramidonGlycopeptidesBombesinTriazolesAmidesIn vitro3. Good healthBioavailabilityReceptors Bombesinchemistry030220 oncology & carcinogenesisMolecular MedicineBombesinNeprilysin
researchProduct

Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat.

2000

The objectives of this study were to determine the oral bioavailability of cefuroxime (C) and to evaluate the pharmacokinetic model that best describes the plasma concentration behaviour following single intravenous (IV), intraperitoneal (IP) and oral single doses. The same dose of C was administered by IV, IP and oral routes to three separate groups of rats (2.02 mg of cefuroxime axetil (CA) by the oral route or 1.78 mg of cefuroxime sodium (CNa) by IV and IP route). A two-compartment open model without lag time can predict the C disposition kinetics. The influence of the administration route on the pharmacokinetic parameters and AUC values was investigated by means of a one-way analysis o…

MaleCefuroximebusiness.industryPharmaceutical ScienceAdministration OralPharmacologyBioavailabilityRatsRoute of administrationPharmacokineticsOral administrationBlood plasmaMedicineAnimalsProdrugsRats WistarbusinessCefuroximeCefuroxime SodiumAntibacterial agentmedicine.drugInternational journal of pharmaceutics
researchProduct

Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans

2013

The objective of this study was to investigate the potential of λ-carrageenan to work as an absorption modifying excipient in combination with formulations of BCS class 3 substances. Trospium chloride was used as a model BCS class 3 substance. Polyelectrolyte complexes of trospium and λ-carrageenan were produced by layer-by-layer complexation. A λ-carrageenan-containing formulation was administered either in capsules size 9 to rats by gavage or directly into ligated intestinal loops of rats. Exceptionally strong variations were observed in the plasma concentrations of the rats that received λ-carrageenan compared to the control group, but enhanced plasma concentrations were observed only in…

MaleCell Membrane PermeabilityNortropanesBiological AvailabilityPharmaceutical ScienceExcipientMuscarinic AntagonistsAbsorption (skin)In Vitro TechniquesBenzilatesCarrageenanTight JunctionsElectrolyteschemistry.chemical_compoundMucoadhesionmedicineAnimalsHumansIntestinal MucosaRats WistarDrug CarriersChromatographyUssing chamberReproducibility of ResultsGeneral MedicinePermeationPolyelectrolyteRatsCarrageenanBioavailabilityMucusJejunumIntestinal AbsorptionSolubilitychemistryCaco-2 CellsBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound

2005

Various particle sizes of spironolactone as a model low solubility drug were formulated to yield micro-and nanosuspensions of the type solid lipid nanoparticles and DissoCubes. Seven oral and one i.v. formulations were tested in an in vivo pharmacokinetic study in rats with the aim of characterizing the bioavailability of spironolactone on the basis of its metabolites canrenone and 7-alpha-thiomethylspirolactone. In addition, a dose escalation study was carried out using nonmicronized spironolactone suspension as well as a nanosuspension type DissoCubes. On the basis of AUC as well as Cmax ratios, three groups of formulations were distinguished. The biggest improvement was seen with a solid…

MaleChemistry PharmaceuticalCmaxAdministration OralBiological AvailabilityPharmaceutical ScienceSpironolactonePharmacologyDrug Delivery SystemsPharmacokineticsPulmonary surfactantOral administrationDrug DiscoverySolid lipid nanoparticlemedicineAnimalsCanrenoneRats WistarSolubilityDiureticsPharmacologyChemistryOrganic ChemistryRatsBioavailabilityArea Under Curvemedicine.drugDrug Development and Industrial Pharmacy
researchProduct

Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo mode…

2003

The purpose of this study was to explore the intestinal absorption mechanism of acamprosate and to attempt to improve the bioavailability (BA) of the drug through modulation of its intestinal absorption using two enhancers (polysorbate 80 and sodium caprate) based on in situ, in vitro and in vivo models and comparing the results obtained. Intestinal transport of the drug, in the absence and in presence of polysorbate 80 (0.06, 0.28 and 9.6 mM) or sodium caprate (13 and 16 mM) was measured by using an in situ rat gut technique and Caco-2 cell monolayers. Additionally, the effect of sodium caprate on drug oral bioavailability, measured as urinary recovery, was quantified by performing in vivo…

MaleChemistryTaurineAcamprosateCell MembranePharmaceutical ScienceAbsorption (skin)PharmacologyIn vitroIntestinal absorptionBioavailabilityRatsAcamprosatePharmacokineticsIntestinal AbsorptionIn vivoParacellular transportmedicineElectric ImpedanceAnimalsHumansCaco-2 CellsRats Wistarmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin.

2016

This work aimed at finding an innovative vesicle-type formulation able to improve the bioavailability of curcumin upon oral administration. To this purpose, phospholipid, Eudragit® S100 and hyaluronan sodium salt were combined to obtain eudragit-hyaluronan immobilized vesicles using an easy and environmentally-friendly method. For the first time, the two polymers were combined in a system intended for oral delivery, to enhance curcumin stability when facing the harsh environment of the gastrointestinal tract. Four different formulations were prepared, keeping constant the amount of the phospholipid and varying the eudragit-hyaluronan ratio. The freeze-drying of the samples, performed to inc…

MaleCurcuminPhospholipidPharmaceutical ScienceBiological Availability02 engineering and technology010402 general chemistry01 natural sciencesIntestinal absorptionchemistry.chemical_compoundFreeze-dryingPolymethacrylic AcidsAnimalsTissue DistributionHyaluronic AcidRats WistarLiposomeChromatographyVesicleGeneral Medicine021001 nanoscience & nanotechnology0104 chemical sciencesBioavailabilityRatsFreeze DryingchemistryIonic strengthLiposomesCurcumin0210 nano-technologyBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Buccal Delivery of Methimazole as an Alternative Means for Improvement of Drug Bioavailability: Permeation Studies and Matrix System Design

2012

The aim of this study was to investigate the potential for systemic administration of Methimazole (MMI) through the buccal mucosa as an alternative route for drug delivery. Considering that the most important restriction in buccal drug delivery could be the low permeability of the mucosa, the ability of MMI to cross the mucosal barrier was assessed. Permeation of MMI through porcine buccal mucosa was investigated ex vivo using Franz type diffusion cells, buffer solution simulating saliva or natural human saliva as donor phase. The collected data suggested that buccal mucosa does not hinder MMI diffusion and the drug crosses the membrane (J(s) = 0.068 mg cm(-2) h(-1) and K(p) = 0.065 cm h(-1…

MaleDrugSwinemedia_common.quotation_subjectAcrylic ResinsBiological AvailabilityPharmacologyPermeabilityDosage formDiffusionExcipientsDrug Delivery SystemsAntithyroid Agentsstomatognathic systemDrug DiscoveryAnimalsHumansSalivamedia_commonPharmacologyMethimazoleChromatographyChemistryMouth MucosaAdministration BuccalBuccal administrationPermeationBioavailabilitySolubilityDrug deliverySystemic administrationEx vivoTabletsCurrent Pharmaceutical Design
researchProduct

Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

2008

Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-m…

MaleDrugmedicine.medical_specialtyGeneral Mathematicsmedia_common.quotation_subjectCancer therapyGeneral Physics and AstronomyAntineoplastic AgentsNerve Tissue Proteinsanti-mitotic drugReviewVinblastineMicrotubulesModels Biologicalanti-mitotic proteinTubulinCell Line TumorNeoplasmsKAR-2Biomarkers TumormedicineAnimalsHumanscancerRats WistarIntensive care medicinemedia_commonTPPP/p25Dose-Response Relationship Drugbusiness.industryGeneral EngineeringCancermedicine.diseaseRatsDrug marketbioavailabilitybusinessPhilosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences
researchProduct

Pharmacokinetics, bioavailability and absorption of flumequine in the rat.

1999

Abstract The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0.94±0.04) and not significantly different from that found by the intraduodenal route (0.95±0.04). The rate of oral bioavailability, however, is slow ( k a =1.20±0.07 h −1 ; T max =2.0 h), but enough to maintain plasma levels above the minimal inhibitory concentration of the most common pathogens for an extended period of time (about 10 h). The reason for the oral absorption slowness could be a slow gastric emptying, an adsorption to the gastric mucosae, a precipitation in the gastric medium or any other feature concerning the stomach as the i…

MaleDuodenumPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalRandom AllocationPharmacokineticsAnti-Infective AgentsOral administrationEnterohepatic CirculationmedicineAnimalsRats WistarEnterohepatic circulationAntibacterial agentGastric emptyingChemistryStomachGeneral MedicineBioavailabilityRatsmedicine.anatomical_structureIntestinal AbsorptionFlumequineQuinolizinesBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Inhibition of cancer growth by resveratrol is related to its low bioavailability.

2002

The relationship between resveratrol (RES) bioavalability and its effect on tumor growth was investigated. Tissue levels of RES were studied after i.v. and oral administration of trans-resveratrol (t-RES) to rabbits, rats, and mice. Half-life of RES in plasma, after i.v. administration of 20 mg t-RES/kg b.wt., was very short (e.g., 14.4 min in rabbits). The highest concentration of RES in plasma, either after i.v. or oral administration (e.g., 2.6 +/- 1.0 microM in mice 2.5 min after receiving 20 mg t-RES/kg orally), was reached within the first 5 min in all animals studied. Extravascular levels (brain, lung, liver, and kidney) of RES, which paralleled those in plasma, were always1 nmol/g f…

MaleEndotheliumMelanoma ExperimentalBiological AvailabilityVascular Cell Adhesion Molecule-1ResveratrolPharmacologyIn Vitro TechniquesIntegrin alpha4beta1medicine.disease_causeBiochemistrychemistry.chemical_compoundMiceOral administrationPhysiology (medical)StilbenesmedicineCell AdhesionAnimalsTissue DistributionRats Wistarchemistry.chemical_classificationKidneyReactive oxygen speciesCell growthAntineoplastic Agents PhytogenicBioavailabilityRatsMice Inbred C57BLmedicine.anatomical_structurechemistryBiochemistryLiverResveratrolRabbitsOxidative stressCell DivisionHalf-LifeFree radical biologymedicine
researchProduct